In:
BioMedica, Discover STM Publishing Ltd., Vol. 36, No. 2S ( 2020-06-26), p. 130-136
Kurzfassung:
〈 p 〉 Since the COVID-19 outbreak has emerged, every nation and every government are trying its best to combat the disease and develop strategies for better prevention, diagnosis, treatment and management of this lethal virus. Though the mortality rate is far less than any other pandemic the world has experienced, still patients with co-morbid conditions and immune system disorders are at high risk of fatal outcome. There are no approved treatments for COVID-19; thus, people with COVID-19 should be referred to clinical trials. Several agents have been touted as treatments for COVID-19, but at this point, the data are insufficient to inform a recommendation for or against the use of these agents outside of clinical trials; well-conducted randomized trials will be critical in determining how COVID-19 should be treated. 〈 /p 〉
Materialart:
Online-Ressource
ISSN:
2710-3471
DOI:
10.51441/BioMedica//BioMedica/5-448
Sprache:
Englisch
Verlag:
Discover STM Publishing Ltd.
Publikationsdatum:
2020
